LEGACY Cohort - Rx monitoring AZA/Tacro in SLE pregnancy Ab#0586 #ACR23 @RheumNow 70 pregnancie. 33% prescribed AZA, 9% TAC AZA - 91% subtherapeutic or non-adherent More likely in non-Caucasian, on steroids, longer SLE duration, prior lupus nephritis TAC - 3/6 therapeutic levels

Do probiotics improve psoriatic arthritis? Unfortunately no difference in disease activity compared to placebo. Limited effects on gut dysbiosis Minor effects on T cell composition @RheumNow #ACR23 Abs#0778 https://t.co/JuBesyfnV2

Targeted OX40L (co-stimulatory APC protein w/ possible polymorphisms in SLE) study by Womba et al, found OX40L targeted CAR-Tregs had superior in vitro suppression of activated T cells & dendritic cells relative to Control-Tregs. #ACR23 Abs 0799 https://t.co/GgCGGIvhHF @rheumnow https://t.co/GZMEUCTooh

Should the cost of #CAR-T stop us from considering in severe refractory #lupus? So far update of German group show remission - drug free and great safety. But hold on..we need RCTs with an active control and longer f/u, but I am impressed! #ACR23 #ACRbest @ACRheum @RheumNow #784 https://t.co/mRMWLCbpCY

Klein et al. 205 RA-ILD. MUC5B not significantly associated survival, although wide CIs, aHR 0.75 (0.45, 1.24). Abstr#0772 #ACR23 @RheumNow https://t.co/ZfIIr2BbbR https://t.co/47DPYWNpL9

#ACR23 tidbits from Sunday @ACRheum @RheumNow 1 Less steroids better w other #Rx in #GCA, #PMR, #SLE #nephritis, #nonrenal #lupus BUT NOT in Severe GCA 2 Trend for combined immune modulators in #lupus GN or w a #CNI 3 #HCQ is better than sliced bread in #SLE aim for drug level

#ACR23 Lower persistance of TNFi in women than men in Psa👍🇫🇷🇫🇷🇫🇷 CHU Mondor @RheumNow https://t.co/27OVLz4aZN

Biologic persistance rates consistently lower in women vs men with PsA. 52% vs 62% @ 1 year. Some statistically significant, but really it is a consistent message across drugs. We urgently need research on the reasons. Abstr#0779 #ACR23 @RheumNow https://t.co/Kfk3k3LJ44 https://t.co/SmiOnt7D4d

Risk factor for 1st Thrombosis in OB APS Ab#0115 #ACR23 @RheumNow 186 OAPS pts, followed mean 5.4 yrs. 11 thrombotic events Risk factors: Triple pos APS Abs (OR 11.6), hypocomplementemia (OR 9) Low dose Aspirin (OR 0.14), HCQ (OR 0.11) reduced thrombosis #ACRBest https://t.co/y4KaEAZzA7

🆕 Imaging modality: MSOT multispectral optoacoustic tomography Findings PsA enthesis -Hyperemia ↗️ oxygenation So2 and Hboxy -Reduction Collagen concentration -Lipids substitution But surprise PSO pts display similar signs despite abs of symptoms! @RheumNow ABST0750 #ACR23 https://t.co/qWMvmIRd7j

#ACR23 Convergence Preview https://t.co/oCdYnS1HdC https://t.co/A6klTchrrG

• ACR Convergence Preview (11.10.2023) | RheumNow

FAPα possible therapeutic biomarker target of pathogenic fibroblasts. #ACR23 Abs 0802 demonstrates potential therapeutic efficacy of fibroblast-targeted immunotherapy as a novel treatment in inflammatory disease. https://t.co/ZGUfC6PZxa @rheumnow https://t.co/jj9BeuvTuc

Abs#518 @RheumNow #ACR23 Deodhar: TOFA in AS, by b/l CRP levels 30% nml CRP (<5 mg/L) v 70% Elevated At wk 12, TOFA >> PBO regardless of b/l CRP Difference in response: greater in pts w elevated CRP Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub

Are Long-term NSAIDs safe in AS? Ab#0528 #ACR23 @RheumNow 19,775 AS pts vs 59,325 controls. Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)